OpenBilldrug price receipt

NADAC week of 2026-10-14

INVOKAMET XR 50-1,000 MG TAB

FDA nonproprietary name: canagliflozin and metformin hydrochloride

For 30 tablets

Pharmacies pay

$290.63 filed

30 × $9.68763 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$278.64 filed

30 × $9.28811 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

0.96× estimated

Medicare paid about what pharmacies pay.

Part D averages every strength and form sold under “Invokamet XR” / “Canagliflozin/Metformin HCl” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$339.22 estimated

$290.63 + $43.59 (15%) + $5.00 fee per fill = $339.22

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

INVOKAMET XR 50-1,000 MG TAB is how the CMS NADAC file names this product. The FDA NDC Directory lists it as canagliflozin and metformin hydrochloride, under the trade name “INVOKAMET XR”.

FDA gives its dosage form as tablet, film coated, extended release and its route as oral.

The labeler, the company named on the label, is Janssen Pharmaceuticals, Inc.

FDA lists it under 2 Established Pharmacologic Classes: Biguanide and Sodium-Glucose Cotransporter 2 Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 50458-0941-01.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $290.63 for 30 tablets (30 × $9.68763 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

The NDC

Other strengths, forms and brands

7 other products in the NADAC file share the FDA nonproprietary name canagliflozin and metformin hydrochloride with INVOKAMET XR 50-1,000 MG TAB.

ProductPharmacies pay per unitMedicare per unit
INVOKAMET 50-1,000 MG TABLET
brand · tablet, film coated
$9.53833 per EA filed
eff. 2026-09-23
$9.31128 per EA filed
Part D 2024 average
INVOKAMET 50-500 MG TABLET
brand · tablet, film coated
$9.56363 per EA filed
eff. 2026-09-23
$9.31128 per EA filed
Part D 2024 average
INVOKAMET 150-1,000 MG TABLET
brand · tablet, film coated
$9.57542 per EA filed
eff. 2026-09-23
$9.31128 per EA filed
Part D 2024 average
INVOKAMET 150-500 MG TABLET
brand · tablet, film coated
$9.60887 per EA filed
eff. 2026-09-23
$9.31128 per EA filed
Part D 2024 average
INVOKAMET XR 50-1,000 MG TAB this page
brand · tablet, film coated, extended release
$9.68763 per EA filed
eff. 2026-09-23
$9.28811 per EA filed
Part D 2024 average
INVOKAMET XR 50-500 MG TABLET
brand · tablet, film coated, extended release
$9.67753 per EA filed
eff. 2025-12-17
$9.28811 per EA filed
Part D 2024 average
INVOKAMET XR 150-1,000 MG TAB
brand · tablet, film coated, extended release
$9.53579 per EA filed
eff. 2026-09-23
$9.28811 per EA filed
Part D 2024 average
INVOKAMET XR 150-500 MG TABLET
brand · tablet, film coated, extended release
$9.56119 per EA filed
eff. 2026-09-23
$9.28811 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-12-17, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $9.68763 per EA filed.

Of the 71 other products in FDA’s Biguanide class priced per EA, 12 have a higher middle NADAC price and 59 a lower one. The one in the middle is SYNJARDY 12.5-1,000 MG TABLET, at $5.60127 per EA filed (eff. 2026-09-23).

Of the 39 other products in FDA’s Sodium-Glucose Cotransporter 2 Inhibitor class priced per EA, 16 have a higher middle NADAC price and 23 a lower one. The one in the middle is XIGDUO XR 5 MG-1,000 MG TABLET, at $9.59236 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $278.64 for 30 tablets, at an average of $9.28811 per EA in 2024 (2024-01-01 to 2024-12-31) for “Invokamet XR” and “Canagliflozin/Metformin HCl”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 10,648 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for INVOKAMET XR 50-1,000 MG TAB labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Invokamet XR / Canagliflozin/Metformin HCl: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.